June 2, 2020 by Chain Drug Review
African-American, blood glucose, sleep apnea, type 2 diabetes
June 1, 2020
BETHESDA, Md. — African-Americans with severe sleep apnea and other adverse sleep patterns are much more likely to have high blood glucose levels — a risk factor for diabetes — than those without these patterns, according to a new study funded in part by the National Heart, Lung and Blood Institute (NHLBI), part of the
May 19, 2018 by Chain Drug Review
American Association of Diabetes Educators., Angela Forfia, Medicare, type 2 diabetes
Pharmacy
WASHINGTON — Millions of U.S. seniors can now take part in a Medicare program designed to prevent prediabetes from progressing to type 2 diabetes. Almost half of Americans 65 and older have prediabetes, and many don’t know it. In addition to an increased risk of type 2 diabetes, prediabetes puts people at risk of heart
January 11, 2018 by Bill Schiffner
AstraZeneca, Bydureon BCise, Rod Wooten, type 2 diabetes, Virginia Valentine
Pharmacy, Supplier News
WILMINGTON, Del. — AstraZeneca announced that Bydureon BCise (exenatide extended-release injectable suspension 2 mg) is now available in pharmacies across the United States. Bydureon BCise was recently approved by the U.S. Food and Drug Administration for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral antidiabetic medicines in addition to
June 9, 2017 by Chain Drug Review
American Diabetes Association, free health screenings, George Riedl, largest health fair in America, Tamara Darsow, type 2 diabetes, Walmart, Walmart Wellness Day
Featured Articles, Leading Headlines, Pharmacy, Retail News
BENTONVILLE, Ark. — This year, Walmart is extending the reach of Walmart Wellness Day, billed as the “largest health fair in America.” On June 17, Walmart plans to offer free health screenings — including blood pressure, blood glucose, body mass index (BMI) — at its more than 4,600 stores nationwide from 10 a.m. to 2
May 4, 2017 by Chain Drug Review
insulin pen, Novo Nordisk, Steve Edelman, Taking Control of Your Diabetes, Tresiba, type 2 diabetes, Victoza, Xultophy 100/3.6
Pharmacy, Supplier News
PLAINSBORO, N.J. — Novo Nordisk has launched Xultophy 100/3.6, a combination therapy insulin pen, at pharmacies nationwide. Xultophy 100/3.6 combines the long-acting basal insulin Tresiba (insulin degludec U-100) with the No. 1-prescribed glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy Victoza (liraglutide 3.6 mg/ml) in a once-daily injection, Novo Nordisk said. The prefilled pen is indicated as
January 4, 2017 by Chain Drug Review
insulin injection, Peter Guenter, Sanofi, Soliqua 100/33, type 2 diabetes
Pharmacy, Supplier News
PARIS — Sanofi has released Soliqua 100/33, an insulin injection for type 2 diabetes, to U.S. pharmacies. The company said Wednesday that Soliqua 100/33 (insulin glargine 100 units/ml and lixisenatide 33 mcg/ml) comes in a single, prefilled SoloStar pen with a dosage range of 15 to 60 units and two starting doses to support patients’
September 13, 2016 by Chain Drug Review
BlueStar diabetes management platform, Johnson & Johnson Diabetes Care, Kevin McRaith, LifeScan, OneTouch Verio Flex, type 2 diabetes, WellDoc
Leading Headlines, Supplier News, Technology
COLUMBIA, Md. — Health technology provider WellDoc has entered a commercial partnership with LifeScan Inc., a unit of Johnson & Johnson Diabetes Care Cos., to deliver a digital health solution for type 2 diabetes nationwide. Plans call for the companies to integrate WellDoc’s clinically validated BlueStar diabetes management platform and mobile application with LifeScan’s OneTouch
July 29, 2016 by Chain Drug Review
Adlyxin, FDA's Center for Drug Evaluation and Research, lixisenatide, Mary Thanh Hai Parks, Peter Guenter, Sanofi, type 2 diabetes
Pharmacy, Supplier News
PARIS — Sanofi has gained Food and Drug Administration approval for Adlyxin (lixisenatide), a medication for type 2 diabetes. A once-daily mealtime GLP-1 receptor agonist injection, Adlyxin is indicated as an adjunct to diet and exercise for improving blood glucose control in the treatment of adults with type 2 diabetes.Sanofi said this week that Adlyxin
August 27, 2015 by Chain Drug Review
Boehringer Ingelheim, Eli Lilly, Paul Fonteyne, Synjardy, type 2 diabetes
Pharmacy, Supplier News
RIDGEFIELD, Conn., and INDIANAPOLIS — Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co. have received approval from the Food and Drug Administration for Synjardy tablets, a medication for type 2 diabetes. The companies said Thursday that Synjardy (empagliflozin and metformin hydrochloride) marks their third product containing empagliflozin to be approved by the FDA, following